:max_bytes(150000):strip_icc()/expe1-653585e289a44fd1aff6678a25611dfe.jpg)
Shares plunge after management reins in its full-year revenue guidance range after reporting a blowout quarter. What happened Shares of Exact Sciences (EXAS 1.73%), a diagnostics company focused on colon cancer, dropped by 12% as of 12:30 p.m. EDT after the company announced its third-quarter earnings.
Full Answer
Where can I buy shares of EXAs?
Jan 12, 2022 · Shares of medical diagnostic company Exact Sciences ( EXAS -6.40%) fell by a jaw-dropping 41% over the whole of 2021, according to data provided by S&P Global Market Intelligence. Although the ...
Is exact sciences (EXAs) losing money in 2021?
Shares of Exact Sciences ( EXAS 1.73%), a diagnostics company focused on colon cancer, dropped by 12% as of 12:30 p.m. EDT after the company announced its …
What is exact sciences'(EXAs) stock symbol?
Jan 12, 2022 · Shares of medical diagnostic company Exact Sciences (NASDAQ: EXAS) fell by a jaw-dropping 41% over the whole of 2021, according to data …
How much of Exact Sciences'stock are insiders selling?
Feb 17, 2021 · Shares of Exact Sciences ( EXAS-0.41%) were sinking 9.2% as of 2:52 p.m. EST on Wednesday. ... Why Exact Sciences Stock Plunged in 2021. 2 Reasons to Buy Exact Sciences Stock, and 1 Reason to Sell ...
See more
Get the latest Exact Sciences Corporation (EXAS) stock news and headlines to help you in your trading and investing decisions.
Is Exas a good stock to buy?
Is Exas overvalued?
Is cologuard publicly traded?
...
Exact Sciences (company)
| Innovation One, the headquarters of Exact Sciences in Madison, Wisconsin (2020). | |
|---|---|
| Type | Public |
| Traded as | Nasdaq: EXAS Russell 1000 Index component |
Is exact science profitable?
Does Pfizer own Cologuard?
In 2018, when Exact Sciences hired Pfizer to co-promote Cologuard, Pfizer was a very different company. Shortly after signing the agreement with Exact Sciences, Pfizer's former CEO Ian Read handed the leadership role to Albert Bourla.Dec 1, 2021
Can I do Cologuard instead of colonoscopy?
What company produces Cologuard?
Shares plunge after management reins in its full-year revenue guidance range after reporting a blowout quarter
Brian Feroldi has been covering the healthcare and technology industries for The Motley Fool since 2015. Brian's investing strategy is to buy high-quality companies and then let compounding work its magic. See all of his articles here. Follow @brianferoldi
What happened
Shares of Exact Sciences ( NASDAQ:EXAS), a diagnostics company focused on colon cancer, dropped by 12% as of 12:30 p.m. EDT after the company announced its third-quarter earnings.
So what
Exact Sciences had a strong quarter. Here's a look at a few of the highlights:
Now what
It's possible demand will slow in the fourth quarter, which wouldn't be great news. However, it's also possible that management is simply trying to keep a lid on investors' expectations so the company can once again report blowout numbers in the fourth quarter.
The company reported disappointing Q4 results
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
Shares of Exact Sciences ( NASDAQ:EXAS) were sinking 9.2% as of 2:52 p.m. EST on Wednesday. The decline came after the diagnostics company reported disappointing fourth-quarter results following the market close on Tuesday.
So what
The big bottom-line miss really shouldn't be worrisome to investors. Exact Sciences' research and development expense was much greater than what analysts projected due to the acquisition of Base Genomics. Adjusting for this acquisition expense, the company's net loss would have only been around $25 million -- better than Wall Street's estimate.
Now what
Don't expect Exact Sciences to report blowout first-quarter results. The company expects screening and COVID-19 testing revenue will decline sequentially. However, the long-term prospects for Exact Sciences continue to look promising.
10 Best Stocks to Buy for the Next Ten Years
In this article, we will examine the reasons why Cathie Wood is sticking to her innovation-centric strategy despite lower than expected performance in the first half of 2021. We will also review the 10 best stocks to buy for the next ten years based on Cathie Wood’s Q2 portfolio. You can skip our detailed discussion […]
3 Top Healthcare Stocks to Buy for August
With excellent prospects, these three companies are built to last and today's prices are attractive.
Bear of the Day: NeoGenomics (NEO)
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top
Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.
Exact Sciences (EXAS) Q2 2021 Earnings Call Transcript
Thank you, Leah, and thanks all of you for joining us for Exact Sciences second-quarter 2021 conference call. On the call today are Kevin Conroy, the company's chairman and CEO; Jeff Elliott, our chief financial and chief operating officer; and Jake Orville, general manager of our pipeline.
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of -43.06% and 3.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Exact Sciences a buy right now?
16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 3 hold ratings, 12 buy ratings and 1 strong buy rating for the stock.
What stocks does MarketBeat like better than Exact Sciences?
Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Exact Sciences wasn't one of them.
When is Exact Sciences' next earnings date?
Exact Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.#N#View our earnings forecast for Exact Sciences.
How were Exact Sciences' earnings last quarter?
Exact Sciences Co. (NASDAQ:EXAS) released its quarterly earnings results on Tuesday, July, 27th. The medical research company reported ($1.03) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.72) by $0.31.
How has Exact Sciences' stock been impacted by COVID-19?
Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EXAS stock has increased by 79.3% and is now trading at $103.65.#N#View which stocks have been most impacted by COVID-19.
What guidance has Exact Sciences issued on next quarter's earnings?
Exact Sciences updated its FY 2021 earnings guidance on Wednesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.71 billion-$1.75 billion, compared to the consensus revenue estimate of $1.72 billion.
What price target have analysts set for EXAS?
16 equities research analysts have issued 1 year price objectives for Exact Sciences' stock. Their forecasts range from $120.00 to $180.00. On average, they anticipate Exact Sciences' share price to reach $151.06 in the next twelve months.
How many cancer cases will there be in 2040?
The National Cancer Institute estimates that new cases per year will rise to 29.5 million by 2040. Annual expenditures for cancer in the U.S. top $150 billion. And these will only rise in the future as the population ages and more individuals test positive.
Where is Cologuard located?
Based in Madison, Wisconsin, the company provides cancer screening and diagnostic tests in the U.S. and abroad. Its leading product is Cologuard, a noninvasive DNA screening test to detect colorectal cancer and pre-cancer. It also offers Oncotype DX, a gene expression test for breast, prostate and colon cancers.
Is Exact Sciences a liquid biopsy?
Exact Sciences is refining tests that detect several kinds of cancer with a simple blood draw, known as a "liquid biopsy.".
What is the name of the test that detects cancer?
Exact Sciences is refining tests that detect several kinds of cancer with a simple blood draw, known as a "liquid biopsy.". Current cancer screenings require invasive endoscopies, radiographic scans or tissue biopsies. Many cancers can't be screened for at all. Moreover, most cancer is detected too late.
Can cancer be detected too late?
Many cancers can't be screened for at all. Moreover, most cancer is detected too late. When Exact Sciences' technology is commercialized, it will represent a historic breakthrough in cancer diagnosis, making cancer screening a routine part of the blood tests that patients get during their annual physicals.
Why is genomic sequencing important?
Cheaper genomic sequencing has allowed researchers to identify genetic mutations associated with many cancers. It has also enabled drug companies to develop targeted therapies. Over the past 10 years, researchers around the world have published thousands of studies that revealed cancer clues detectable in blood.
What company acquired Thrive earlier detection?
In January, Exact Sciences completed its acquisition of Thrive Earlier Detection, a cancer-screen developer, for $2.15 billion. Last year, researchers discovered that Thrive's technology found previously undetected cancer in 26 patients, including ovarian cancer - for which no screening exists.
Recently Viewed Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
Exact Sciences Corp
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
